Compounded semaglutide in 2026: still available, on borrowed time
If you're seeing $99–199/month "semaglutide" offers in 2026 and wondering how that's still a thing after the shortage ended — here is the actual answer, without the marketing gloss from either side.
The short version
- Mass compounding of semaglutide and tirzepatide ended in spring 2025 when the FDA declared the shortages over.
- What survives is patient-specific compounding (503A): a prescription written for you with a documented clinical reason the approved product doesn't fit — a different dose, a "microdose," an added ingredient like B12, or an oral/sublingual form.
- Regulators and manufacturers are actively squeezing that lane: an FDA proposal from April 2026 would close the bulk-compounding door permanently; the FDA sent 30 warning letters to telehealth marketers in March 2026; Eli Lilly and Novo Nordisk are suing providers over "personalization" they call pretextual.
- Compounded GLP-1s are not FDA-approved — nobody has reviewed the specific product you'd receive for safety, effectiveness, or manufacturing quality.
How we got here
During the 2022–2024 shortages, federal law allowed compounding pharmacies to make "essentially copies" of semaglutide and tirzepatide, and a huge telehealth industry grew on top of that. The FDA declared the tirzepatide shortage over in December 2024 and semaglutide in February 2025; wind-down deadlines for copies passed in April–May 2025. Compounders sued (the Outsourcing Facilities Association cases); they lost at the district level for both drugs, and the appeals were argued at the Fifth Circuit in spring 2026 — no decision as of this writing.
The "personalization" lane, and why it's contested
503A compounding legally exists for patients an approved product doesn't serve — a documented allergy, a dose that doesn't come off the shelf, a form a patient can't take. Today's compounded-GLP-1 telehealth industry runs on prescriptions written this way: microdose tiers, semaglutide-plus-B12, sublingual drops, dissolving tablets. Providers argue this is legitimate individualized medicine. Lilly's lawsuits (against Mochi Health and others) argue the "personalization" is a script — the same few "custom" formulations prescribed to nearly everyone — making the products copies with extra steps. Courts haven't settled it. Meanwhile the FDA's March 3, 2026 warning-letter sweep hit 30 telehealth companies, mostly for marketing compounded products as equivalent to approved drugs and for white-labeling compounded drugs under telehealth brand names.
The two events that decide this market
- The FDA's 503B rule. In April 2026 the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the list of drugs outsourcing facilities may compound in bulk, on "no clinical need" grounds. Comments closed in June 2026; a final determination is pending. If finalized, patient-specific 503A prescriptions become the only remaining lane.
- The Fifth Circuit ruling in the compounders' appeal. A compounder win would reopen doors; a loss cements the wind-down.
Either could land any month. Which is why our advice to anyone choosing a compounded program is the same regardless of provider:
If you're on (or considering) a compounded GLP-1
- Have a plan B. Know today which branded option you'd switch to and what it costs — likely the Wegovy pill ($149–199/mo) or Foundayo (from $149/mo). Providers forced to stop compounding will push you somewhere; better to have picked in advance.
- Avoid long prepaid commitments. A 12-month compounded prepay is a bet that a contested legal pathway outlives your contract. Month-to-month terms (e.g., Mochi) carry less of this risk than commitment plans (Found).
- Do the fresh math. Since FDA-approved pills arrived at $149–199/month, the compounded discount is often $0–50/month. For many people the gray-zone trade-off no longer buys much.
- Only ever use providers requiring a real prescription. Anything sold without a prescriber evaluation — "research peptides," no-Rx websites, gray-market vials — is a different and dangerous category entirely. We don't list those at any price, or any commission.
Bottom line
Legal-but-contested, available-but-narrowing. Compounded GLP-1s in August 2026 are a real option with a real discount and a real expiration risk. Go in with a documented clinical rationale, month-to-month terms, a plan B, and your own doctor's input — or skip the question entirely with a $149 FDA-approved pill.
Compare all providers See every cash price